title: [Prevalence of serotypes causing invasive pneumococcal disease in the region of Tarragona, Spain, 2006-2009: vaccine-serotype coverage for the distinct antipneumococcal vaccine formulations].
abstract: BACKGROUND
  Pneumococcal infections remain a major health problem worldwide. This study analysed the distribution of distinct Streptococcus pneumoniae serotypes causing invasive pneumococcal disease (IPD) among all-age population in the region of Tarragona (Spain) throughout 2006-2009.
  
  
  METHODS
  An amount of 237 strains were evaluated, of which 203 (85.7%) were isolated from blood cultures, 14 (5.9%) from pleural fluids, 13 (5.5%) from CSF samples and 7 (3%) from other sterile sites. Forty-seven cases (19.8%) were children ≤ 14 years, 94 (39.7%) were patients 15-64 years and 96 (40.5%) were patients ≥ 65 years.
  
  
  RESULTS
  Seven serotypes (1, 3, 6A, 7F, 12F, 14 and 19A) caused almost two thirds (63.3%) of cases among all-age patients. Serotype 1 was the most common serotype among children (44.7%) and among people 15-64 years (21.3%), whereas serotype 19A was the most common among people ≥ 65 years (12.5%).Among all-age population, serotype-vaccine coverage for the distinct pneumococcal polysaccharide vaccine (PPV) and conjugate vaccines (PCVs) were 17.3% for the PCV7, 49.8% for the PCV10, 73% for the PCV13 and 80.2% for the PPV23 (p < 0.001). Among children, vaccine-serotype coverage was 23.4% for the PCV7, 72.3% for the PCV10 and 83% for the PCV13. Among people ≥ 65 years, vaccine-serotype coverage was 62.5% for the PCV13 and 68.8% for the PPV23.
  
  
  CONCLUSIONS
  A considerable proportion of IPD cases among our population would not be covered by the current pneumococcal vaccines.
authors.affiliation: Olga Ochoa Gondar, Servicio de Atención Primaria Camp de Tarragona. ICS, Rambla Nova 124, D, 1ºA. 43001. Tarragona, Spain. oochoa.tarte.ics@gencat.cat.
authors.forename: Olga
authors.initials: O
authors.lastname: Ochoa-Gondar
authors.forename: Frederic
authors.initials: F
authors.lastname: Gómez-Bertomeu
authors.forename: Angel
authors.initials: A
authors.lastname: Vila-Córcoles
authors.forename: Xavier
authors.initials: X
authors.lastname: Raga
authors.forename: Carlos
authors.initials: C
authors.lastname: Aguirre
authors.forename: Jesús
authors.initials: J
authors.lastname: Utrera
authors.forename: Cinta
authors.initials: C
authors.lastname: de Diego
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Guzmán
authors.forename: Enric
authors.initials: E
authors.lastname: Figuerola
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D002626:Chemistry, Pharmaceutical; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000382:microbiology*; D022242:Pneumococcal Vaccines / Q000627:therapeutic use*; D015995:Prevalence; D062486:Public Health Surveillance; D065288:Serogroup; D013030:Spain / Q000453:epidemiology; D013296:Streptococcus pneumoniae / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000276:immunology; D055815:Young Adult
chemical_list: D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate